Washington, DC (PRWEB) September 14, 2009
Cardiocore, a premier centralized cardiac testing lab, announced today that it has been selected by one of the world's top five biotechnology companies to provide both electrocardiographic (ECG) and echocardiographic (ECHO) analyses for a multinational, natural history study.
Cardiocore will provision and provide 24/7/365 support to investigative sites in North America, Latin America, Eastern Europe, Western Europe, Africa, and countries in the Asia-Pacific region such as Taiwan and South Korea. At these globally distributed sites, pediatric patients suffering from metabolic disease will be tracked for 96 months. During that time their cardiac safety profile will be periodically assessed.
ECG tests will examine study subjects' cardiac electric conductivity, while concurrent ECHO scans will appraise the structure and mechanical function of their heart muscles and valves. Cardiocore will generate and format comprehensive datasets comprising ECG and ECHO results that will be used for control comparisons in additional research projects.
Cardiocore will also provide specialized scientific and medical services related to the study's pediatric population. Cardiocore Vice President of Medical Operations, Polina Voloshko, MD noted, "Pediatric ECG analysis is quite different from adult ECG reading. Morphology assessment and diagnostic thresholds vary significantly throughout childhood development. So, in order to provide the highest possible level of pertinent expertise, all ECGs will be read by Cardiocore's board certified pediatric cardiologists."
Anatomic changes in childhood also require expert techniques in ECHO analysis. Cardiocore Senior Scientist and founder of the UCSF Echocardiography Laboratory, Nelson Schiller, MD, FACC explained, "For this disease, early identification of left ventricular wall thickening may provide opportunities to manage underlying causes and prevent heart failure. As the pediatric study subjects' anatomy develops during 8 years of testing, Cardiocore's ECHO analysis system will apply data such as height and weight to accurately index left ventricular mass measurements. With this technique, each patient's cardiac dimensions will always be appraised relative to changes in their overall body mass."
"We are pleased to extend our relationship with this large biotechnology organization until 2017 and beyond," added Cardiocore CEO, Jennifer Cotteleer, "and we are proud to continue delivering them the expert science, global services and advanced data management necessary to make this important project successful."
About Cardiocore: Cardiocore has provided superior centralized cardiac testing services to the pharmaceutical industry for 17 years. Services include centralized electrocardiography (ECG), Holter monitoring, echocardiography (ECHO), multigated acquisition scans (MUGA), protocol development and statistical analysis. The company is experienced in cardiac safety and efficacy testing in Phase I-IV and Thorough QT clinical trials. These services are supported by the company's advanced data management system featuring the proprietary HolterGateway™ and CardioPortal™. Cardiocore's U.S. headquarters is located in Bethesda, Maryland, its West Coast office is located in San Francisco, California, and its European subsidiary, Cardiocore Limited, is located in London, England. http://www.cardiocore.com
# # #